Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities

Vaccine

Volumn 28, Issue 45, 2010, Pages 7273-7278

  Maher, Lisa ^a   White, Bethany ^a   Hellard, Margaret ^b   Madden, Annie ^c   Prins, Maria ^d   Kerr, Thomas ^e   Page, Kimberly ^f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c Australian Injecting and Illicit Drug Users' League (AIVL)   (Australia)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e ST PAUL S HOSPITAL   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis C virus; People who inject drugs; Vaccine

Indexed keywords

HEPATITIS C VACCINE;

ARTICLE; CLINICAL TRIAL; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PLANNING; HEPATITIS C; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFECTION RISK; INFORMED CONSENT; METHODOLOGY; NONHUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; RESEARCH ETHICS; RISK REDUCTION;

CLINICAL TRIALS AS TOPIC; DRUG USERS; HEPATITIS C; HUMANS; INFORMED CONSENT; STANDARD OF CARE; VIRAL HEPATITIS VACCINES;

EID: 77957750866     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.085     Document Type: Article

References (99)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
2. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
3. Wong J.B. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006, 24:661-672.
4. Razali K., Thein H.H., Bell J., Cooper-Stanbury M., Dolan K., Dore G., et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007, 91:228-235.
5. Page-Shafer K., Hahn J.A., Lum P.J. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007, 21:1967-1969.
6. Barnes E. Hepatitis C virus 2010, World Health Organization Initiative for Vaccine Research, Available from: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html#disease%20burden [cited 2010 6 August].
7. Strickland G.T., El-Kamary S.S., Klenerman P., Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008, 8:379-386.
8. Centers for Disease Control Prevention Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001, 1-42.
9. Yazdanpanah Y., De Carli G., Migueres B., Lot F., Campins M., Colombo C., et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005, 41:1423-1430.
10. WHO Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6:35-47.
11. Mitchell A.E., Colvin H.M., Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010, 51:729-733.
12. Hagan H., Pouget E.R., Des Jarlais D.C., Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008, 168:1099-1109.
13. Judd A., Hickman M., Jones S., McDonald T., Parry J.V., Stimson G.V., et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. Br Med J 2005, 330:24-25.
14. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101:1499-1508.
15. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002, 155:645-653.
16. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002, 186:1558-1564.
17. Page K., Hahn J.A., Evans J., Shiboski S., Lum P., Delwart E., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009, 200:1216-1226.
18. Maher L., Li J., Jalaludin B., Chant K.G., Kaldor J.M. High hepatitis C incidence in new injecting drug users: a policy failure?. Aust N Z J Public Health 2007, 31:30-35.
19. van Ameijden E.J., Van den Hoek J.A., Mientjes G.H., Coutinho R.A. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993, 9:255-262.
20. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010, 105:844-859.
21. Hernandez-Aguado I., Ramos-Rincon J.M., Avinio M.J., Gonzalez-Aracil J., Perez-Hoyos S., de la Hera M.G. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol 2001, 17:539-544.
22. Kapadia F., Vlahov D., Des Jarlais D.C., Strathdee S.A., Ouellet L., Kerndt P., et al. Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users?. Epidemiology 2002, 13:738-741.
23. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102:1454-1462.
24. Garfein R.S., Golub E.T., Greenberg A.E., Hagan H., Hanson D.L., Hudson S.M., et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS 2007, 21:1923-1932.
25. Hahn J., Wylie D., Dill J., Sanchez M.S., Lloyd-Smith J.O., Page-Shafer K., et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009, 1:47-57.
26. Salomon J.A., Weinstein M.C., Hammitt J.K., Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003, 290:228-237.
27. Castelnuovo E., Thompson-Coon J., Pitt M., Cramp M., Siebert U., Price A., et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users 2006, University of Southampton, Southampton, 10(32).
28. National Centre in HIV Epidemiology Clinical Research Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010, The University of New South Wales, Sydney, NSW.
29. Volk M.L., Tocco R., Saini S., Lok A.S. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
30. Hagan H., Latka M.H., Campbell J.V., Golub E.T., Garfein R.S., Thomas D.A., et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006, 42:669-672.
31. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
32. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bowden D.S., Bharadwaj M., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1746-1752.
33. Krahn M.D., John-Baptiste A., Yi Q., Doria A., Remis R.S., Ritvo P., et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 2005, 23:1549-1558.
34. Houghton M., Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436:961-966.
35. Lauer G.M., Chung R.T. Vaccine-induced T-cell responses against HCV: one step taken, more to follow. Gastroenterology 2007, 132:1626-1628.
36. Rosen H.R. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003, 9:S35-S43.
37. Gale M., Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436:939-945.
38. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
39. Forns X., Payette P.J., Ma X., Satterfield W., Eder G., Mushahwar I.K., et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000, 32:618-625.
40. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2009, 138:315-324.
41. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.H., et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004, 78:1575-1581.
42. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
43. Dore G.J., Micallef J. Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity?. Hepatology 2007, 45:1130.
44. Wedemeyer H., Schuller E., Schlaphoff V., Stauber R.E., Wiegand J., Schiefke I., et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009, 27:5142-5151.
45. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134:1385-1395.
46. Gowans E.J., Roberts S., Jones K., Dinatale I., Latour P.A., Chua B., et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010, 10.1016/j.jhep.2010.05.007.
47. Drane D., Maraskovsky E., Gibson R., Mitchell S., Barnden M., Moskwa A., et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccine 2009, 5:151-157.
48. Frey S.E., Houghton M., Coates S., Abrignani S., Chien D., Rosa D., et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010, 10.1016/j.vaccine.2010.06.084.
49. Farci P., Purcell R.H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000, 20:103-126.
50. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973.
51. Kuiken C., Combet C., Bukh J., Shin I.T., Deleage G., Mizokami M., et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology 2006, 44:1355-1361.
52. Folgori A., Barnes E., Aston S., Smith K., Ambrosio M., Ammendola V., et al. Phase I trial of a highly immunogenic T cell vaccine for hepatitis C virus based on novel, rare, adenoviral vectors [Oral presentation]. 6th International Symposium on Hepatitis C Virus and Related Viruses; 2009 2009.
53. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006, 12:190-197.
54. Telles P.R., Lum P., Hahn J., Ellman A., Edlin B., Kral A., et al. HCV subtypes 2 & 3 emerging as significant subtypes among IDU in San Francisco [Oral presentation]. 3rd International Workshop on HIV and Hepatitis Coinfection 2007.
55. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007, 14:413-418.
56. van Asten L., Verhaest I., Lamzira S., Hernandez-Aguado I., Zangerle R., Boufassa F., et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004, 189:292-302.
57. Newman P.A., Duan N., Lee S.J., Rudy E.T., Seiden D.S., Kakinami L., et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 2006, 24:2094-2101.
58. Newman P.A., Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010, 24:1749-1756.
59. Lugoboni F., Migliozzi S., Schiesari F., Pauletto N., Bovo G.L., Ciaffoni S., et al. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine 1997, 15:1014-1016.
60. Buchbinder S.P., Metch B., Holte S.E., Scheer S., Coletti A., Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004, 36:604-612.
61. Doab A., Topp L., Day C.A., Dore G.J., Maher L. Clinical trial literacy among injecting drug users in Sydney, Australia: a pilot study. Contemp Clin Trials 2009, 30:431-435.
62. Kwon J.A., Iversen J., Maher L., Law M.G., Wilson D.P. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr 2009, 51:462-469.
63. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
64. Kerr T., Montaner J., Wood E. Supervised injecting facilities: time for scale-up?. Lancet 2008, 372:354-355.
65. Kamal S.M., Fouly A.E., Kamel R.R., Hockenjos B., Al Tawil A., Khalifa K.E., et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006, 130:632-638.
66. Institute of Medicine Methodological challenges in biomedical HIV prevention trials 2008, Institute of Medicine, Washington, DC.
67. Lagakos S.W., Gable A.R. Challenges to HIV prevention-seeking effective measures in the absence of a vaccine. N Engl J Med 2008, 358:1543-1545.
68. Dhalla S., Poole G., Singer J., Patrick D.M., Wood E., Kerr T. Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users. Vaccine 2010, 28:1663-1667.
69. Vanichseni S., Tappero J.W., Pitisuttithum P., Kitayaporn D., Mastro T.D., Vimutisunthorn E., et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS 2004, 18:311-316.
70. Wood E., Werb D., Marshall B.D., Montaner J.S., Kerr T. The war on drugs: a devastating public-policy disaster. Lancet 2009, 373:989-990.
71. Thorpe L.E., Ouellet L.J., Levy J.R., Williams I.T., Monterroso E.R. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 2000, 182:1588-1594.
72. Maher L., White B., Donald A., Bates A., Enriquez J., Pham S., et al. Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs. Int J Drug Policy 2010, 21:194-201.
73. Brooks R.A., Newman P.A., Duan N., Ortiz D.J. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 2007, 19:52-58.
74. Harrison R.W. Impact of biomedical research on African Americans. J Natl Med Assoc 2001, 93:6S-7S.
75. Kerr T., Small W., Wood E. The public health and social impacts of drug market enforcement: a review of the evidence. Int J Drug Policy 2005, 16:210-220.
76. Small W., Kerr T., Charette J., Schechter M., Spittal P.M. Impacts of intensified police activity on injection drug users: evidence from an ethnographic investigation. Int J Drug Policy 2006, 17:85-95.
77. Maher L., Dixon D. Policing and public health-law enforcement and harm minimization in a street-level drug market. Br J Criminol 1999, 39:488-512.
78. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 2006, 41:210-217.
79. Maher L., Bates A., Coupland H., Enriquez J., Ho H.T., Le T.T., et al. We are family: ICON a model for effective peer-based outreach targeting marginalised injecting drug users. Theory, evidence and context: contemporary innovations in alcohol and other drug practice in Australia 2008, Oxford University Press, Melbourne. D. Moore, P. Deitze (Eds.).
80. Nguyen O.K., Dore G.J., Kaldor J.M., Hellard M.E. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy 2007, 18:447-451.
81. Blower S., Schwartz E.J., Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. AIDS Rev 2003, 5:113-125.
82. Schechter M., Do Lago R.F., Mendelsohn A.B., Moreira R.I., Moulton L.H., Harrison L.H. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004, 35:519-525.
83. van Griensvan F., Keawkungwal J., Tappero J.W., Sangkum U., Pitisuttithum P., Vanichseni S., et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 2004, 18:295-301.
84. Baral S., Sherman S.G., Millson P., Beyrer C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 2007, 7:667-674.
85. van Houdt R., Koedijk F.D., Bruisten S.M., Coul E.L., Heijnen M.L., Waldhober Q., et al. Hepatitis B vaccination targeted at behavioral risk groups in the Netherlands: does it work?. Vaccine 2009, 27:3530-3535.
86. Campbell J.V., Garfein R.S., Thiede H., Hagan H., Ouellet L.J., Golub E.T., et al. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend 2007, 91:S64-S72.
87. Seal K.H., Kral A.H., Lorvick J., McNees A., Gee L., Edlin B.R. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003, 71:127-131.
88. Des Jarlais D.C., Fisher D.G., Newman J.C., Trubatch B.N., Yancovitz M., Paone D., et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health 2001, 91:1791-1792.
89. Wright N.M., Campbell T.L., Tompkins C.N. Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health 2002, 5:324-326.
90. Tolley E.E., Severy L.J. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health 2006, 96:79-83.
91. Levy V., Evans J.L., Stein E.S., Davidson P.J., Lum P.J., Hahn J.A., et al. Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?. Vaccine 2010, 28:5947-5951.
92. Treloar C., Byron P., McCann P., Maher L. Fitness for duty: social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. Vaccine 2010, 28:5228-5236.
93. Davis M., Rhodes T., Martin A. Preventing hepatitis C: 'common sense' 'the bug' and other perspectives from the risk narratives of people who inject drugs. Soc Sci Med 2004, 59:1807-1818.
94. Page-Shafer K., Saphonn V., Sun L.P., Vun M.C., Cooper D.A., Kaldor J.M. HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia. Lancet 2005, 366:1499-1503.
95. Crofts N., Aitken C.K., Kaldor J.M. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999, 170:220-221.
96. Johnston M.I., Fauci A.S. An HIV vaccine-challenges and prospects. N Engl J Med 2008, 359:888-890.
97. McMichael A. Prospects for an AIDS vaccine. Clin Med 2003, 3:269-272.
98. Hallinan R., Byrne A., Amin J., Dore G.J. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005, 20:1082-1086.
99. McCarthy J.J., Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001, 20:19-31.